scispace - formally typeset
R

Richard A. Flavell

Researcher at Yale University

Publications -  1389
Citations -  223064

Richard A. Flavell is an academic researcher from Yale University. The author has contributed to research in topics: Immune system & T cell. The author has an hindex of 231, co-authored 1328 publications receiving 205119 citations. Previous affiliations of Richard A. Flavell include National Institute for Medical Research & University of Michigan.

Papers
More filters
Journal ArticleDOI

A dominant function for interleukin 27 in generating interleukin 10–producing anti-inflammatory T cells

TL;DR: It is demonstrated that dendritic cells modified by Treg cells induced the generation of IL-10-producing Tr1 cells, and IL-27 and transforming growth factor-β promote the generation.
Journal ArticleDOI

TGF-β: A Master of All T Cell Trades

TL;DR: This work has defined the cytokine transforming growth factor-beta as a critical regulator of thymic T cell development as a crucial player in peripheral T cell homeostasis, tolerance to self antigens, and T cell differentiation during the immune response.
Journal ArticleDOI

RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement

TL;DR: The response to RNA-associated autoantigens was markedly enhanced by IFN-α, a cytokine strongly linked to disease progression in patients with systemic lupus erythematosus (SLE), and this data implicate TLR recognition of endogenous ligands in the response to both DNA- and RNA- associated autoantIGens.
Journal ArticleDOI

Mice deficient for the CD40 ligand.

TL;DR: The study confirms the important role of CD40-CD40L interactions in thymus-dependent humoral immune responses and germinal center formation and indicates an inability to develop memory B cell responses.
Journal ArticleDOI

Transforming growth factor-beta in T-cell biology.

TL;DR: In vitro studies provide a better understanding of how TGF-β regulates T-cell homeostasis, through multiple mechanisms involving numerous cell types, and advances in cell-specific targeting of T GF-β signalling in vivo clearer.